Codexis Inc (CDXS)
$5.72 -$0.09 (-1.53%) 10:04 AM 12/12/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$384.92M -
Day's Range
$5.64 - $5.86 -
Volume
702,483 -
52 Week Low / High
$1.85 - $5.00 -
PE Ratio
- -
PEG Ratio
-1.16 -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 4
- Strong Buy
- 1
- Buy
- 2
- Hold
- 0
- Sell
- 0
- Strong Sell
- $7.71
- Target Price
Company News
-
Codexis to Report Third Quarter 2024 Financial Results on October 31 — Oct 10th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on T...
-
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences — Oct 1st, 2024
Codexis, Inc. Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications REDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme en...
-
Codexis to Report Third Quarter 2024 Financial Results on October 31 — Oct 10th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on T...
-
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences — Oct 1st, 2024
Codexis, Inc. Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications REDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme en...
-
Codexis to Report Third Quarter 2024 Financial Results on October 31 — Oct 10th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on T...
-
Codexis Announces New Employment Inducement Grants — Oct 14th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to eight new employees as approved by the Comp...
-
Codexis Announces New Employment Inducement Grants — Oct 14th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to eight new employees as approved by the Comp...
-
Codexis Announces New Employment Inducement Grants — Oct 14th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to eight new employees as approved by the Comp...
-
Codexis to Report Third Quarter 2024 Financial Results on October 31 — Oct 10th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on T...
-
Codexis Announces New Employment Inducement Grants — Oct 14th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to eight new employees as approved by the Comp...
-
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences — Oct 1st, 2024
Codexis, Inc. Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications REDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme en...
-
Codexis to Report Third Quarter 2024 Financial Results on October 31 — Oct 10th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on T...
-
Codexis Announces New Employment Inducement Grants — Oct 14th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to eight new employees as approved by the Comp...
-
Codexis to Report Third Quarter 2024 Financial Results on October 31 — Oct 10th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on T...
-
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences — Oct 1st, 2024
Codexis, Inc. Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications REDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme en...
-
Codexis to Report Third Quarter 2024 Financial Results on October 31 — Oct 10th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on T...
-
Codexis Announces New Employment Inducement Grants — Oct 14th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to eight new employees as approved by the Comp...
-
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences — Oct 1st, 2024
Codexis, Inc. Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications REDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme en...
-
Codexis Announces New Employment Inducement Grants — Oct 14th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to eight new employees as approved by the Comp...
-
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences — Oct 1st, 2024
Codexis, Inc. Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications REDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme en...
-
Codexis to Report Third Quarter 2024 Financial Results on October 31 — Oct 10th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on T...
-
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences — Oct 1st, 2024
Codexis, Inc. Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications REDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme en...
-
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences — Oct 1st, 2024
Codexis, Inc. Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications REDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme en...
-
Codexis Announces New Employment Inducement Grants — Oct 14th, 2024
Codexis, Inc. REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to eight new employees as approved by the Comp...
Portfolio
Comprised of 1 portfolios